Two PD-1 inhibitors, Bristol-Myers Squibb's nivolumab and Merck's MK-3475, both 
demonstrated positive results in phase I trials of previously treated patients 
with non-small cell lung cancer, reported at the World Conference on Lung Cancer 
in Sydney, Australia.